Clinical response and outcome of infection with Salmonella enterica serotype typhi with decreased susceptibility to fluoroquinolones: A United States FoodNet multicenter retrospective cohort study

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1278-1284

  Crump, John A ^a,b   Kretsinger, Katrina ^a,b   Gay, Kathryn ^a   Hoekstra, R Michael ^a   Vugia, Due J ^c   Hurd, Sharon ^d   Segler, Susan D ^e   Megginson, Melanie ^f   Luedeman, L Jeffrey ^g   Shiferaw, Beletshachew ^h   Hanna, Samir S ⁱ   Joyce, Kevin W ^a   Mintz, Eric D ^a   Angulo, Frederick J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d Georgia Emerging Infections Program ^*  (United States)

^e Georgia Emerging Infections Program   (United States)

^f MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^g MINNESOTA DEPARTMENT OF HEALTH   (United States)

^h OREGON DEPARTMENT OF HUMAN SERVICES   (United States)

ⁱ TENNESSEE DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CLINICAL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SALMONELLA ENTERICA; SALMONELLOSIS; SEROTYPE; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; FOOD POISONING; HOSPITALIZATION; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; SALMONELLA TYPHI; TREATMENT OUTCOME; TYPHOID FEVER; UNITED STATES;

EID: 42049093980     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01509-07     Document Type: Article

References (29)

1. Aarestrup, F. M., C. Wiuff, K. Molbak, and E. J. Threlfall. 2003. Is it time to change the fluoroquinolone breakpoints for Salmonella spp? Antimicrob. Agents Chemother. 47:827-829.
2. Ackers, M.-L., N. D. Puhr, R. V. Tauxe, and E. D. Mintz. 2000. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA 283:2668-2673.
3. Alios, B. M., M. R. Moore, P. M. Griffin, and R. V. Tauxe. 2004. Surveillance for sporadic foodborne disease in the 21st century: the FoodNet perspective. Clin. Infect. Dis. 38(Suppl. 3):S115-S120.
4. Anderson, E. S. 1975. The problem and implication of chloramphenicol resistance in the typhoid bacillus. J. Hyg. 74:289-299.
5. Biedenbach, D. J., M. Toleman, T. R. Walsh, and R. N. Jones. 2006. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY antimicrobial surveillance program (1997-2004). Diagn. Microbiol. Infect. Dis. 54:13-21.
6. Center for Disease Control. 1972. Typhoid fever: Mexico. MMWR Morb. Mortal. Wkly. Rep. 21:177-178.
7. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Cooke, F. J., M. Day, J. Wain, L. R. Ward, and E. J. Threlfall. 2007. Cases of typhoid fever imported into England, Scotland and Wales (2000-3). Trans. R. Soc. Trop. Med. Hyg. 101:398-404.
9. Crump, J. A., T. J. Barrett, J. T. Nelson, and F. J. Angulo. 2003. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin. Infect. Dis. 37:75-81.
10. Crump, J. A., S. P. Luby, and E. D. Mintz. 2004. The global burden of typhoid fever. Bull. W. H. O. 82:346-353.
11. Eaves, D. J., L. Randall, D. T. Gray, A. Buckley, M. J. Woodward, A. P. White, and L. J. V. Piddock. 2004. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica. Antimicrob. Agents Chemother. 48:4012-4015.
12. Edelman, R., and M. M. Levine. 1986. Summary of an international workshop on typhoid fever. Rev. Infect. Dis. 8:329-349.
13. Gay, K., A. Robicsek, J. Strahilevitz, C. H. Park, G. Jacoby, T. J. Barrett, F. Medalla, T. M. Chiller, and D. C. Hooper. 2006. Plasmid-mediated quinolone resistance on non-Typhi serotypes of Salmonella enterica. Clin. Infect. Dis. 43:297-304.
14. Hall, T. A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41:95-98.
15. Hooper, D. C., J. S. Wolfson, K. S. Souza, E. Y. Ng, G. L. McHugh, and M. N. Swartz. 1989. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation. Antimicrob. Agents Chemother. 33:283-290.
16. Kadhiravan, T., N. Wig, A. Kapil, S. K. Kabra, K. Renuka, and A. Misra. 2005. Clinical outcomes in typhoid fever: adverse impact of infection with nalidixic acid-resistant Salmonella Typhi. BMC Infect. Dis. 5:37.
17. Lynch, M., S. Bulens, C. Polyak, E. Blanton, F. Medalla, T. J. Barrett, and E. D. Mintz. 2005. Multidrug-resistance among Salmonella Typhi isolates in the United States, 1999-2003, abstr. 101. Abstr. 6th Int. Conf. Typhoid Fever Other Salmonelloses.
18. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. National Committee for Clinical Laboratory Standards, Wayne, PA.
19. Paniker, C. K. J., and K. N. Vilma. 1972. Transferable chloramphenicol resistance in Salmonella Typhi. Nature 239:109-110.
20. Rahman, M. M., J. A. Haq, M. A. H. G. Morshed, and M. A. Rahman. 2005. Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin: an emerging problem in Bangladesh. Int. J. Antimicrob. Agents 25:345-353.
21. Rowe, B., L. R. Ward, and E. J. Threlfall. 1997. Multidrug-resistant Salmonella Typhi: a worldwide epidemic. Clin. Infect. Dis. 24:S106-S109.
22. Shirakawa, T., B. Acharya, S. Kinoshita, S. Kumagai, A. Gotoh, and M. Kawabata. 2006. Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar Typhi and Paratyphi A isolated from Kathmandu, Nepal, in 2003. Diagn. Microbiol. Infect. Dis. 54:299-303.
23. Slinger, R., M. Desjardins, A. E. McCarthy, K. Ramotar, P. Jessamine, C. Guibord, and B. Toye. 2004. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect. Dis. 4:36.
24. Threlfall, E. J., B. Rowe, and L. R. Ward. 1991. Occurrence and treatment of resistant Salmonella Typhi. Public Health Laboratory Service Microbiol. Digest 8:56-59.
25. Threlfall, E. J., L. R. Ward, J. A. Skinner, H. R. Smith, and S. Lacey. 1999. Ciprofloxacin-resistant Salmonella Typhi and treatment failure. Lancet 353: 1590-1591.
26. van den Bergh, E. T. A. M., G. M. Hussein, M. Keuter, and M. V. Dolmans. 1999. Outcome in three groups of patients with typhoid fever in Indonesia between 1948 and 1990. Trop. Med. Int. Health 4:211-215.
27. Wain, J., N. T. T. Hoa, N. T. Chinh, H. Vinh, M. J. Everett, T. S. Diep, N. P. J. Day, T. Solomon, N. J. White, L. J. V. Piddock, and C. M. Parry. 1997. Quinolone-resistant Salmonella Typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin. Infect. Dis. 25:1404-1410.
28. Walia, M., R. Gaind, R. Mehta, P. Paul, P. Aggarwal, and M. Kalaivani. 2005. Current perspectives of enteric fever: a hospital-based study from India. Ann. Trop. Paediatr. 25:161-174.
29. Zeller, V., C. Janoir, M. D. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.